期刊
MOLECULAR AND CELLULAR ENDOCRINOLOGY
卷 301, 期 1-2, 页码 51-58出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2008.07.015
关键词
Steroid metabolism; Ovarian cancer; 17 beta-Hydroxysteroid dehydrogenase; 3 beta-Hydroxysteroid dehydrogenase; 3 alpha-Hydroxysteroid dehydrogenase; Estrone sulfatase
资金
- Susan G. Komen Foundation
- Gynecologic Cancer Foundation
Anti-estrogen therapies for treating ovarian carcinoma have had mixed outcomes suggesting some tumors may be estrogen-dependent. We assayed the activity levels of 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD), 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD), 3 alpha-hydroxysteroid dehydrogenase (3 alpha-HSD/3-KSR) and estrone sulfatase in a series of ovarian epithelial carcinomas. 17 beta-HSD activity ratios with estradiol (E-2) and testosterone (T), and inhibition by isoform-specific inhibitors were used to estimate the contributions of 17 beta-HSD isoforms. Activity levels were highest for estrone sulfatase, followed, respectively by 17 beta-HSD, 3 alpha-HSD/3-KSR, and 3 beta-HSD. E-2/T activity ratios varied widely between samples. A 17 beta-HSD type 1 inhibition pattern was observed in 23% of the samples and a type 2 pattern in 25%. E-2 formation from estrone sulfate ((ES)-S-1) was detected in 98% (47/48) of the samples. 17 beta-HSD type 1, type 2 and type 5 mRNA was detected in matched primary tumor and metastases. Evaluation of 17 beta-HSD and sulfatase activity levels, activity ratios and inhibition patterns may help predict tumor response to endocrine therapy. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据